Broncus (HKG:2216) plans to repurchase up to 52,719,807 of its shares on the market, representing around 10% of the total number of its issued shares, a Thursday Hong Kong bourse filing said.

The medical device company will make repurchases on the market from time to time until its next annual general meeting or until the share repurchase mandate is revoked.

The company will fund the repurchase with its existing cash reserves.